Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jeremy Fryzuk Insider Profile
4 Followers
Jeremy Fryzuk, Director at Bright Minds Biosciences, holds 4.61K shares in Bright Minds Biosciences (Ticker: TSE:DRUG).
Jeremy Fryzuk Bright Minds Biosciences (DRUG)Director
Bright Minds Biosciences (DRUG)
Director
Ranked #11,135 out of 100,516 Corporate Insiders
Profitable Transactions
4 out of 5 Profitable Transactions
Average Return
+33.60%
Average return per transaction
Time Frame
Compare to
Insider Roles
Director
Roles that Jeremy Fryzuk holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Aug 25, 2022 - Aug 25, 2023
Return:+80.00%
The most profitable trade made by Jeremy Fryzuk
Jeremy Fryzuk's Trading History
List of latest transactions for each holding click on a transaction to see Jeremy Fryzuk's performance on stock
You May Also Like
Jeremy Fryzuk insider profile FAQ
What is the percentage of profitable transactions made by Jeremy Fryzuk?
The percentage of profitable transactions made by Jeremy Fryzuk is 80%.
What is the average return per transaction made by Jeremy Fryzuk?
The average return per transaction made by Jeremy Fryzuk is 33.60%.
What stocks does Jeremy Fryzuk hold?
Jeremy Fryzuk holds: TSE:DRUG stocks.
What was Jeremy Fryzuk’s latest transaction?
Jeremy Fryzuk latest transaction was an Uninformative Sell of ―.
What was Jeremy Fryzuk's most profitable transaction?
Jeremy Fryzuk’s most profitable transaction was an Informative Sell of TSE:DRUG stock on August 25, 2022. The return on the trade was 80.00%.
What is Jeremy Fryzuk's role in Bright Minds Biosciences?
Jeremy Fryzuk's role in Bright Minds Biosciences is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.